BioNTech SE - ADR
NASDAQ:BNTX 4:00:00 PM EDT
| Market Cap (Intraday) | 24.67B |
| Current PE | 3.95 |
| Forward PE | 18.79 |
| 2yr Forward PE | 33.97 |
| 10-Day MA | $110.64 |
| 50-Day MA | $111.71 |
| 200-Day MA | $124.90 |
BioNTech SE - ADR Stock, NASDAQ:BNTX
An der Goldgrube 12, Mainz, Rheinland-Pfalz 55131
Germany
Phone: +49.6131.9084.0
Number of Employees: 4530
Description
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.